Figure 3From: XELIRI-bevacizumab versus FOLFIRI-bevacizumab as first-line treatment in patients with metastatic colorectal cancer: a Hellenic Cooperative Oncology Group phase III trial with collateral biomarker analysis High baseline plasma OPN concentrations (above the median) were significantly associated with shorter OS and PFS. Back to article page